ES2193592T3 - Uso de derivados de la oxazolidinona para el tratamiento de la artritis. - Google Patents
Uso de derivados de la oxazolidinona para el tratamiento de la artritis.Info
- Publication number
- ES2193592T3 ES2193592T3 ES98960157T ES98960157T ES2193592T3 ES 2193592 T3 ES2193592 T3 ES 2193592T3 ES 98960157 T ES98960157 T ES 98960157T ES 98960157 T ES98960157 T ES 98960157T ES 2193592 T3 ES2193592 T3 ES 2193592T3
- Authority
- ES
- Spain
- Prior art keywords
- arthritis
- treatment
- oxazolidinone derivatives
- psoriasis
- oxazolidinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title abstract 2
- 206010003246 arthritis Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 229940030999 antipsoriatics Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Uso de una oxazolidinona seleccionada entre: (S)-N-[[3-[3-fluoro-4-[4-(hidroxiacetil)-1- piperazinil]-fenil]-2-oxo-5-oxazolidinil]metil]acetamida, (S)-N-[[3-[3-fluoro-4-(4-morfolinil)fenil]-2-oxo-5- oxazolidinil]metil]acetamida, [4(S)-cis]-(-)-N-[[3-[3-Fluoro-4-(tetrahidro-1-oxido- 2H-tiopiran-4-il)fenil]-2-oxo-5- oxazolidinil]metil]acetamida, N-((5S)-3-(3-fluoro-4-(4-(2-fluoroetil)-3- oxopiperacin-1-il)fenil)-2-oxooxazolidin-5- ilmetil)acetamida, (S)-N-[[3-[5-(3-piridil)tiofen-2-il]-2-oxo-5- oxazolidinil]metil]acetamida y (S)-N-[[3-[5-(4-piridil)pirid-2-il]-2-oxo-5- oxazolidinil]metil]acetamida y sales farmacéuticamente aceptables de los mismos para la fabricación de un medicamento para el tratamiento de artritis.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6568997P | 1997-11-18 | 1997-11-18 | |
US7129798P | 1998-01-16 | 1998-01-16 | |
US7366298P | 1998-02-04 | 1998-02-04 | |
US7524798P | 1998-02-19 | 1998-02-19 | |
US7767298P | 1998-03-12 | 1998-03-12 | |
PCT/US1998/023233 WO1999025344A1 (en) | 1997-11-18 | 1998-11-10 | Use of oxazolidinone derivatives for treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2193592T3 true ES2193592T3 (es) | 2003-11-01 |
Family
ID=27535698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98960157T Expired - Lifetime ES2193592T3 (es) | 1997-11-18 | 1998-11-10 | Uso de derivados de la oxazolidinona para el tratamiento de la artritis. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1032386B1 (es) |
JP (1) | JP2001522886A (es) |
KR (2) | KR100574307B1 (es) |
CN (2) | CN1546030A (es) |
AT (1) | ATE233092T1 (es) |
AU (1) | AU743941B2 (es) |
BR (1) | BR9815615A (es) |
CA (1) | CA2303961A1 (es) |
DE (1) | DE69811717T2 (es) |
DK (1) | DK1032386T3 (es) |
ES (1) | ES2193592T3 (es) |
HK (1) | HK1036591A1 (es) |
NZ (1) | NZ504612A (es) |
PT (1) | PT1032386E (es) |
SI (1) | SI1032386T1 (es) |
WO (1) | WO1999025344A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU753988B2 (en) | 1998-06-05 | 2002-10-31 | Astrazeneca Ab | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them |
DE60030300T2 (de) * | 1999-09-13 | 2007-08-30 | Insite Vision, Inc., Alameda | Topische behandlung zur vorbeugung von augeninfektionen |
US6451345B1 (en) * | 2000-01-20 | 2002-09-17 | Eurand Pharmaceuticals Ltd. | Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration |
IL139975A0 (en) * | 2000-11-29 | 2002-02-10 | Univ Ramot | Anti proliferative drugs |
WO2005060951A2 (en) * | 2003-12-19 | 2005-07-07 | Bionaut Pharmaceuticals, Inc. | Anti-neoplastic agents, combination therapies and related methods |
CN107456442A (zh) * | 2016-06-03 | 2017-12-12 | 四川赛卓药业股份有限公司 | 一种噁唑烷酮化合物的亚微乳注射剂及其制备方法和用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE146783T1 (de) * | 1991-11-01 | 1997-01-15 | Upjohn Co | Substituierte aryl- und heteroaryl- phenyloxazolidinone |
SK283420B6 (sk) * | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny |
US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
CA2174107C (en) * | 1993-11-22 | 2005-04-12 | Steven J. Brickner | Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones |
-
1998
- 1998-11-10 WO PCT/US1998/023233 patent/WO1999025344A1/en active IP Right Grant
- 1998-11-10 DE DE69811717T patent/DE69811717T2/de not_active Expired - Fee Related
- 1998-11-10 SI SI9830387T patent/SI1032386T1/xx unknown
- 1998-11-10 CA CA002303961A patent/CA2303961A1/en not_active Abandoned
- 1998-11-10 CN CNA2004100027903A patent/CN1546030A/zh active Pending
- 1998-11-10 AU AU15823/99A patent/AU743941B2/en not_active Ceased
- 1998-11-10 EP EP98960157A patent/EP1032386B1/en not_active Expired - Lifetime
- 1998-11-10 PT PT98960157T patent/PT1032386E/pt unknown
- 1998-11-10 KR KR1020007005366A patent/KR100574307B1/ko not_active IP Right Cessation
- 1998-11-10 ES ES98960157T patent/ES2193592T3/es not_active Expired - Lifetime
- 1998-11-10 NZ NZ504612A patent/NZ504612A/xx unknown
- 1998-11-10 AT AT98960157T patent/ATE233092T1/de not_active IP Right Cessation
- 1998-11-10 DK DK98960157T patent/DK1032386T3/da active
- 1998-11-10 JP JP2000520777A patent/JP2001522886A/ja not_active Withdrawn
- 1998-11-10 KR KR1020057017426A patent/KR100589545B1/ko not_active IP Right Cessation
- 1998-11-10 CN CNB988100134A patent/CN1142777C/zh not_active Expired - Fee Related
- 1998-11-10 BR BR9815615-2A patent/BR9815615A/pt not_active Application Discontinuation
-
2001
- 2001-10-26 HK HK01107458A patent/HK1036591A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU743941B2 (en) | 2002-02-07 |
EP1032386B1 (en) | 2003-02-26 |
BR9815615A (pt) | 2000-10-24 |
PT1032386E (pt) | 2003-07-31 |
KR20050100009A (ko) | 2005-10-17 |
DE69811717T2 (de) | 2003-10-16 |
KR100589545B1 (ko) | 2006-06-19 |
CN1546030A (zh) | 2004-11-17 |
JP2001522886A (ja) | 2001-11-20 |
KR20010032178A (ko) | 2001-04-16 |
HK1036591A1 (en) | 2002-01-11 |
NZ504612A (en) | 2002-08-28 |
WO1999025344A1 (en) | 1999-05-27 |
EP1032386A1 (en) | 2000-09-06 |
DK1032386T3 (da) | 2003-05-26 |
DE69811717D1 (de) | 2003-04-03 |
SI1032386T1 (en) | 2003-06-30 |
KR100574307B1 (ko) | 2006-04-27 |
AU1582399A (en) | 1999-06-07 |
CA2303961A1 (en) | 1999-05-27 |
CN1142777C (zh) | 2004-03-24 |
ATE233092T1 (de) | 2003-03-15 |
CN1299281A (zh) | 2001-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2164040T1 (es) | Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos. | |
NZ332762A (en) | Isobutylgaba and its derivatives for the treatment of pain | |
ES2166111T3 (es) | Uso de tiagabina para el tratamiento de trastornos del sueño. | |
DE50214206D1 (de) | Kombinationstherapie substituierter oxazolidinone | |
ES2165441T3 (es) | Inhibidores de calpaina y/o catepsina b oxazolidin sustituidos. | |
ES2116801T3 (es) | Empleo de derivados de adamantano para el tratamiento de tinnitus. | |
BR9502707A (pt) | Composto composição farmacêutica e método para o tratamento de uma afecção | |
NZ307509A (en) | Use of 1L agonists in the treatment of incontinence | |
BR0107667A (pt) | Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo | |
EE200200107A (et) | Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks | |
SE9702564D0 (sv) | New compounds | |
DE60016460D1 (de) | Verwendungen und zusammenstellungen von nitratestern als sedativa | |
ES2083597T3 (es) | Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado. | |
ID21472A (id) | Senyawa terbaru yang berguna sebagai agen pelindung saraf | |
DE69818294D1 (de) | Oxazolidinone derivate und pharmazeutische zusammensetzungen | |
BR0009524A (pt) | Uso de um composto, e, composição farmacêutica ou veterinaria | |
ES2193592T3 (es) | Uso de derivados de la oxazolidinona para el tratamiento de la artritis. | |
AR008860A1 (es) | Empleo de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica | |
MY137595A (en) | N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide for the treatment of cancer | |
PT656209E (pt) | Derivados de melatonina para uso no tratamento de perturbacoes de dessincronizacao | |
ES2187156T3 (es) | Terapia antidepresiva. | |
EP1304107A3 (en) | Use of oxazolidinines derivatives for treating psoriasis | |
NZ331165A (en) | Verotoxin pharmaceutical compositions and medical treatments therewith | |
AR015537A1 (es) | Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina. | |
BR0317772A (pt) | Método de tratamento de um distúrbio de comportamento, uso de um composto, e, agente terapêutico para um distúrbio de comportamento |